Literature DB >> 17160483

Metabolism of N-methyl, N-propargylphenylethylamine: studies with human liver microsomes and cDNA expressed cytochrome P450 (CYP) enzymes.

Katherine A Rittenbach1, Andrew Holt, Lei Ling, Jackie Shan, Glen B Baker.   

Abstract

1. We used an in vitro screening procedure and studies with individual human liver microsomes and cDNA-expressed CYP enzymes to investigate the metabolism of the putative neuroprotective drug N-methyl,N-propargyl-2-phenylethylamine (MPPE) to N-methylphenylethylamine (N-methylPEA) and N-propargylphenylethylamine (N-propargylPEA). 2. An electron-capture gas chromatographic procedure previously developed in our laboratories was used to measure the quantities of N-methylPEA and N-propargylPEA formed in the experiments with a single donor human liver microsome panel and cDNA expressed single CYP enzyme systems. The data were fitted to nonlinear regressions using Prism to determine kinetic constants. The results from a fluorogenic screen determined which cDNA-expressed single CYP enzymes were investigated. 3. CYP2B6, CYP2C19, and CYP2D6 all contributed to the formation of N-methylPEA, while only CYP2B6 catalyzed the formation of N-propargylPEA. The K (M) and V (max) values for N-propargylPEA formation were 290 +/- 70 microM and 139+/-16 ng/mL/min. The values for formation of N-methylPEA were not determined from these experiments due to the complexity of fitting the data to a three-variable equation, but data on the time course of N-methylPEA formation are presented. 4. Catabolism of MPPE to N-methylPEA and N-propargylPEA is catalyzed by CYP enzymes. CYP2B6, 2C19 and 2D6 all contribute to the depropargylation of the parent compound, but only CYP2B6 also catalyzes demethylation. CYP2C19 was found to be the most active with respect to generation of N-methylPEA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160483     DOI: 10.1007/s10571-006-9085-1

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  34 in total

1.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Authors:  S R Faucette; R L Hawke; E L Lecluyse; S S Shord; B Yan; R M Laethem; C M Lindley
Journal:  Drug Metab Dispos       Date:  2000-10       Impact factor: 3.922

Review 2.  Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.

Authors:  M D Berry; A V Juorio; I A Paterson
Journal:  Prog Neurobiol       Date:  1994-10       Impact factor: 11.685

3.  A rapid electron-capture gas chromatographic procedure for the analysis of p-hydroxymephenytoin.

Authors:  M Salsali; R T Coutts; G B Baker
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Nov-Dec       Impact factor: 1.950

Review 4.  Neuroprotection in Parkinson's disease: clinical trials.

Authors:  Fabrizio Stocchi; C Warren Olanow
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

Review 5.  Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration.

Authors:  W G Tatton; R M Chalmers-Redman
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

Review 6.  Selegiline for Alzheimer's disease.

Authors:  J Birks; L Flicker
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 7.  Pharmacologic treatment of Alzheimer's disease: an update.

Authors:  Vincent W DeLaGarza
Journal:  Am Fam Physician       Date:  2003-10-01       Impact factor: 3.292

8.  Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.

Authors:  Orit Bar Am; Tamar Amit; Moussa B H Youdim
Journal:  Neurosci Lett       Date:  2004-01-30       Impact factor: 3.046

Review 9.  Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.

Authors:  E H Heinonen; V Myllylä
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

Review 10.  Newer antidepressants and the cytochrome P450 system.

Authors:  C B Nemeroff; C L DeVane; B G Pollock
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more
  1 in total

Review 1.  Molecular characterization of CYP2B6 substrates.

Authors:  Sean Ekins; Manisha Iyer; Matthew D Krasowski; Evan D Kharasch
Journal:  Curr Drug Metab       Date:  2008-06       Impact factor: 3.731

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.